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Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a novel coronavirus and the primary 
causative agent of coronavirus disease 2019 (COVID-19), first occurred in China and rapidly spread 
worldwide. The government of the Republic of Indonesia confirmed its first two cases of COVID-19 in 
March 2020. COVID-19 is a serious illness with no efficacious antiviral medication or approved vaccine 
currently available. Therefore, there is a need to investigate the genome of SARS-CoV-2. In this study, 
we characterized SARS-CoV-2 spike glycoprotein genes from Indonesia to investigate their genetic 
composition and variability. Overall, ten SARS-CoV-2 spike glycoprotein gene sequences retrieved 
from GenBank (National Center for Biotechnology Information, USA) and the GISAID EpiCoV database 
(Germany) were compared. We analyzed nucleotide variants and amino acid changes using Molecular 
Evolutionary Genetics Analysis (MEGA) X and analyzed gene similarity using the LALIGN web server. 
Interestingly, we revealed several specific mutation sites, however, there were no significant changes 
in the genetic composition of SARS-CoV-2 spike glycoprotein genes, when compared to the Wuhan-
Hu-1 isolate from China. However, this is a preliminary study and we recommend that molecular 
epidemiology and surveillance programs against COVID-19 in Indonesia be improved.  
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INTRODUCTION
 The Chinese government first reported 
a novel pneumonia-causing disease in Wuhan 
in December 20191. The causative agent was 
identified and named severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2) by the 
International Committee on Taxonomy of Viruses 
(ICTV)2. This new virus has rapidly spread across 
China and to many other countries across the 
world, including Indonesia3-4. The World Health 
Organization has named the illness caused 
by SARS-CoV-2 as coronavirus disease 2019 
(COVID-19)5. 
 According to an online interactive 
dashboard hosted by the Center for Systems 
Science and Engineering at Johns Hopkins 
University (Baltimore, USA), which tracks reported 
cases of COVID-19 in real-time6, more than 4 
million people have been infected by SARS-
CoV-2 worldwide, with more than 14 000 cases 
in Indonesia alone. Currently, there are three 
coronaviruses that cause illness in humans: 
severe acute respiratory syndrome coronavirus 
(SARS-CoV), Middle East respiratory syndrome 
coronavirus (MERS-CoV), and SARS-CoV-27. 
 Taxonomically, coronaviruses belong 
to the Coronaviridae  family in the order 
Nidovirales, with examples in four distinct 
genera: Alphacoronavirus, Betacoronavirus, 
Deltacoronavirus, and Gammacoronavirus8. The 
structural proteins are encoded by four genes, 
specifically the envelope (E), nucleocapsid (N), 
membrane (M), and spike glycoprotein (S)7,9-
10. Previous studies have shown that the spike 
glycoprotein plays a crucial role in binding to 
receptors on the host cell. Therefore, this protein 
is a key target for a number of antiviral therapies 
and a promising antigen for generating vaccines 
formulated against SARS-CoV, MERS-CoV, and 
SARS-CoV-2.
 Molecular epidemiology research is a 
crucial tool in the surveillance of newly emerging 
and reemerging viruses11-12. Indonesia was the 
eighth country in Southeast Asia after Brunei, 
Cambodia, Malaysia, Myanmar, Singapore, 
Thailand, and Vietnam to report the whole-
genome sequences of SARS-CoV-2 in the region. 
Both Callaway (2020) and Shang et al. (2020) 
have shown that vaccines are being developed 
against SARS-CoV-2 by various research groups 
worldwide13-14. Similarly, Al-Tawfiq (2020) has 
discussed other potential therapeutic options for 
COVID-1915 and both remdesivir and chloroquine 
are capable of effectively inhibiting SARS-CoV-2 in 
in vitro assays16. Despite these promising treatment 
options, COVID-19 remains a serious disease 
with no proven effective antiviral medication or 
approved vaccine available. Therefore, there is an 
urgent need to investigate the genome of SARS-
CoV-2. In this study, we characterized SARS-CoV-2 
spike glycoprotein genes from Indonesia in order 
to investigate their genetic composition and the 
similarity between different gene isolates.
MATERIALS AND METHODS
SARS-CoV-2 Isolates
 SARS-CoV-2 spike glycoprotein gene 
(3822 bp) sequences were obtained from GenBank 
(National Center for Biotechnology Information, 
USA) and the Global Initiative on Sharing 
All Influenza Data (GISAID) EpiCoV database 
(Germany) (Table 1).
Genetic Composition Analysis
 We analyzed the genetic composition of 
SARS-CoV-2 spike glycoproteins (both nucleotide 
variants and amino acid changes) using Molecular 
Evolutionary Genetics Analysis (MEGA) X12,17. We 
used the Wuhan-Hu-1 isolate as a reference gene, 
according to Sekizuka et al. (2020)18.
Similarity Analysis
 We analyzed the similarity of SARS-CoV-2 
spike glycoprotein genes using the LALIGN web 
server (The SIB Swiss Institute of Bioinformatics, 
Switzerland) with an E-value threshold of 10.0. 
The LALIGN program is based on an algorithm first 
described by Huang and Miller19.
RESULTS AND DISCUSSION
 Coronaviruses infect both animals 
and humans and lead to various illnesses, 
including neurological, enteric, and respiratory 
diseases. There are four distinct genera of 
coronaviruses: Alphacoronavirus, Betacoronavirus, 
Gammacoronavirus, and Deltacoronavirus8. 
SARS-CoV, MERS-CoV, and SARS-CoV-2 are three 
highly pathogenic coronaviruses, capable of 
infecting humans, that emerged in 2002, 2012, 
and 2019, respectively3-4. In this study, the genetic 
compositions and sequence similarities of nine 
Indonesian SARS-CoV-2 spike glycoprotein genes 
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were determined using sequences obtained 
from GenBank and the GISAID EpiCoV database 
(Table 2-4). Many researchers worldwide have 
previously reported mutations in the SARS-CoV-2 
genome10,20-21, however, there has not previously 
been a study of the SARS-CoV-2 genome from 
Indonesian isolates.
 The coronavirus spike glycoprotein 
mediates membrane fusion and viral entry into 
host cells and is therefore the primary target for 
many neutralizing antibodies (Fig. 1). The spike 
glycoprotein has two domains, S1 and S2, where 
S1 is responsible for binding the virion to ACE2 
on the host cell membrane21. Several antiviral 
drugs and vaccines have been developed which 
target the spike glycoprotein. Du et al. (2009)22 
demonstrated the effectiveness of several of these 
antiviral therapies, including small interfering 
RNAs, protease inhibitors, ACE2 blockers, fusion 
blockers, spike glycoprotein inhibitors, neutralizing 
antibodies, and spike glycoprotein cleavage 
inhibitors in in vitro studies. In addition, a number 
of techniques have been used to generate vaccines 
using all or part of the spike glycoprotein as an 
antigen. These include the use of recombinant 
receptor binding domain protein, viral vectors, full-
length S protein, recombinant spike glycoprotein, 
and spike protein DNA-expressing vectors. Thus, 
it is very important to investigate the genetic 
composition and sequence similarity of this 
protein.
 Interestingly, despite reporting several 
mutation sites in this study, we demonstrate 
that there is no significant change in the genetic 
composition of SARS-CoV-2 spike glycoprotein 
genes. Nucleotide variants in SARS-CoV-2 spike 
Table 2. Nucleotide mutation sites in the SARS-CoV-2 spike glycoprotein
 
No. Virus Name    Nucleotide Position
  224 347 414 1715 1841 1864 2031 2464
1 Wuhan-Hu-1 C C T C A G G C
 (Reference) 
2 JKT-EIJK0141 C C T C A G G C
3 JKT-EIJK0317 C C T C A G G C
4 JKT-EIJK2444 T C T C A G G C
5 EJ-ITD853Sp C C T C A G G C
6 EJ-ITD3590NT C G T C G G T C
7 JKT-EIJK01 C C C C A T G C
8 JKT-EIJK02 C C T C A G G C
9 JKT-EIJK03 C C T C A G G C
10 JKT-EIJK04 C C T T A G G T
Table 3. Amino acid mutation sites in the SARS-CoV-2 spike glycoprotein
 
No Virus Name    Amino Acid Position
  76 116 572 614 622 677 822
1 Wuhan-Hu-1 T S T D V Q L
 (Reference) 
2 JKT-EIJK0141 T S T D V Q L
3 JKT-EIJK0317 T S T D V Q L
4 JKT-EIJK2444 I S T D V Q L
5 EJ-ITD853Sp T S T D V Q L
6 EJ-ITD3590NT T C T G V H L
7 JKT-EIJK01 T S T D F Q L
8 JKT-EIJK02 T S T D V Q L
9 JKT-EIJK03 T S T D V Q L
10 JKT-EIJK04 T S I D V Q F
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glycoprotein genes described in this study 
include JKT-EIJK2444 (224C>T), EJ-ITD3590NT 
(347C>G; 1841A>G; 2031G>T), JKT-EIJK01 (414T>C; 
1864G>T), and JKT-EIJK04 (1715C>T; 2464C>T) 
(Table 2). In addition, we also analyzed amino 
acid changes in the SARS-CoV-2 spike glycoprotein 
including JKT-EIJK2444 (T76I), EJ-ITD3590NT 
(S116C; D614G; Q677H), JKT-EIJK01 (V622F), and 
JKT-EIJK04 (T572I; L822F) (Table 3). Finally, the 
interval score of similarity between each of the 
SARS-CoV-2 spike glycoproteins was between 
99.9% and 100% (Table 4). 
 Previous studies investigating gene 
variability in SARS-CoV-2 samples include the 
work of Sekizuka et al. (2020), who performed 
whole-genome sequencing of SARS-CoV-2, directly 
from PCR-positive clinical specimens18. This was 
conducted in order to generate a haplotype 
network analysis of the Diamond Princess cruise 
ship outbreak, using the Wuhan-Hu-1 sequence 
as a reference. Additionally, Castillo et al. (2020) 
reported a phylogenetic analysis of the first four 
SARS-CoV-2 cases in Chile, analyzing nucleotide 
variants, amino acid changes, and sequence 
similarity23. While our study complements these 
previous works, several shortcomings remain, 
including the relatively small number of isolates 
studied, the methodology used for whole-genome 
sequencing, and the quality coverage of SARS-
CoV-2 genomes isolated from Indonesia.
 As new information on SARS-CoV-2 is 
published daily, new concepts and frameworks 
must constantly be adopted. Currently, the 
GISAID EpiCoV database and Tang et al. (2020) 
have established three subtypes of SARS-CoV-2 
based on nucleotide variants that produce amino 
acid changes: S, G, and V24. The mutation rate of 
viruses is considerably higher than most other 
biological entities, including prokaryotes and 
eukaryotes. This is especially true of RNA-based 
viruses such as SARS-CoV-2, Ebola and dengue, 
due to hydroxyl groups in RNA that act as catalytic 
sites for mutation. This advanced mutation rate, 
leads to enhanced virulence and a higher capacity 
for adaptive evolution25-26. While Tang et al. (2020) 
have suggested that SARS-CoV-2 exhibits the 
characteristic high mutation rate of an RNA virus24, 
in fact, the mutation rate of SARS-CoV-2 and other 
coronaviruses might be slightly lower than other 
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exonuclease. Regardless, its high mutation rate 
increases the potential of this zoonotic viral 
pathogen to adapt to efficient transmission from 
human to human and potentially allows it to 
become more virulent.
 The genomic characteristics of SARS‐
CoV‐2 are significantly different than either 
SARS-CoV or MERS‐CoV27. A previous study 
reported that the homology of SARS-CoV-2 
with the bat coronavirus isolate, RaTG13, was 
96%28. Interestingly, another study reported that 
the homology of SARS-CoV-2 with a pangolin 
coronavirus was 99%1. From these results, it could 
be suggested that pangolins act as an intermediate 
host between bats and humans. 
 This study of genomic variants of SARS‐
CoV‐2 isolated from Indonesia is crucial for future 
investigations into the pathogenesis, prevention, 
and treatment of SARS‐CoV‐2. Development of 
this genomic data is vital work that will facilitate 
vaccine design, epidemiological investigations, 
viral detection, functional analysis, and evaluation 
of treatment options27.
 Outbreaks of SARS-CoV-2 have led to 
a state of medical and economic emergency 
worldwide. Therefore, understanding the 
characteristics of the SARS-CoV-2 genome and 
developing systems to monitor SARS-CoV-2 during 
the pandemic are critical steps for controlling this 
disease. The identification of genotypes connected 
to specific geographic and temporal infectious 
clusters suggests that genomic data can be used to 
track and monitor the transmission of SARS-CoV-2. 
Therefore, the rapid discovery of genetic variants 
of SARS-CoV-2 is necessary for a streamlined 
response to the COVID-19 outbreak. Similarly, 
identifying specific SARS-CoV-2 variants and 
connecting them using a molecular epidemiology 
approach would allow researchers to determine 
the origin of a specific variant and monitor its 
transmission. This could be an important tool in 
controlling the outbreak21. 
CONCLUSION 
 In summary, there was no significant 
difference between the SARS-CoV-2 spike 
glycoprotein gene sequences found in Indonesia 
and the Wuhan-Hu-1 isolate from China. However, 
this was only a preliminary study and we 
recommend expanding molecular epidemiology 
and surveillance programs to monitor COVID-19 
in Indonesia.
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